Evidence map›Paper›PMID 30503969›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2019

MicroRNA-621 Acts as a Tumor Radiosensitizer by Directly Targeting SETDB1 in Hepatocellular Carcinoma.

Yingjie Shao, Xing Song, Wenjie Jiang, Yuan Chen, Zhonghua Ning, Wendong Gu, Jingting Jiang

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 73 citations in OpenAlex.

  1. Article
  2. Recent Advances in Cancer Immunotherapy Aided by Regulatory Non-Coding RNA: A Review.Asian Pacific journal of cancer prevention : APJCP · 2025
    Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Application of nano-radiosensitizers in combination cancer therapy.Bioengineering & translational medicine · 2023
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Yingjie ShaoDepartment of Radiation Oncology, The Third Affiliated Hospital of Soochow University, Changzhou 213003, Jiangsu Province, China.
Xing SongDepartment of Radiation Oncology, The Third Affiliated Hospital of Soochow University, Changzhou 213003, Jiangsu Province, China.
Wenjie JiangDepartment of Radiation Oncology, The Third Affiliated Hospital of Soochow University, Changzhou 213003, Jiangsu Province, China.
Yuan ChenDepartment of Radiation Oncology, The Third Affiliated Hospital of Soochow University, Changzhou 213003, Jiangsu Province, China.
Zhonghua NingDepartment of Radiation Oncology, The Third Affiliated Hospital of Soochow University, Changzhou 213003, Jiangsu Province, China.
Wendong GuDepartment of Radiation Oncology, The Third Affiliated Hospital of Soochow University, Changzhou 213003, Jiangsu Province, China. Electronic address: guwendong1415@czfph.com.
Jingting JiangDepartment of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou 213003, China; Jiangsu Engineering Research Center for Tumor Immunotherapy, Changzhou 213003, China. Electronic address: jiangjingting@suda.edu.cn.
Soochow University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Radiotherapy is one of the most important treatment methods of tumors. However, the application of radiotherapy in hepatocellular carcinoma (HCC) is limited due to the low tolerance of normal liver cells for radiation and inherent radiation resistance in HCC. With the in-depth study of microRNAs (miRNAs) in tumor therapy, the regulation of tumor radiosensitivity by miRNAs has been a research hotspot in recent years. In the present study, the expression of miR-621 was lower in HCC tissues and cells, and such low expression of miR-621 was associated with poor prognosis in HCC patients. In addition, in vivo and in vitro assays confirmed that the high expression of miR-621 could significantly enhance the radiosensitivity of HCC. Moreover, the expressions of miR-621 and SETDB1 in HCC tissues were negatively correlated. Dual-luciferase reporter assays indicated that miR-621 could directly target the 3' UTR of SETDB1. In addition, miR-621 enhanced the radiosensitivity of HCC cells via directly inhibiting SETDB1. Besides, the miR-621 and/or SETDB1 axis improved the radiosensitivity of HCC cells via activating the p53-signaling pathway. Taken together, miR-621 and/or SETDB1 might be used as a novel therapeutic target for the treatment of HCC.

Indexed as

MicrowavesAnimalsCarcinoma, HepatocellularCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHep G2 CellsHistone-Lysine N-MethyltransferaseHumansLiver NeoplasmsMiceMice, NudeMicroRNAsRadiation-Sensitizing AgentsSignal TransductionHistone-Lysine N-MethyltransferaseMicroRNAsMIRN621 microRNA, humanRadiation-Sensitizing Agentshepatocellular carcinomamiR-621p53radiosensitivitySETDB1

Identifiers

PMID30503969
PMCPMC6369664
OpenAlexW2900483681

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.